Effect of Selumetinib versus Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

IMPORTANCE: Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in MAPK pathway activation. OBJECTIVE: To assess the efficacy of selumetinib, a selective, non-ATP competitive inhibitor of MEK1 and MEK2, in uveal melanoma. DESIGN: Randomized open-label phase II clinical trial co...

Full description

Saved in:
Bibliographic Details
Published in:JAMA
Main Authors: Carvajal, Richard D., Sosman, Jeffrey A., Quevedo, Jorge Fernando, Milhem, Mohammed M., Joshua, Anthony Michael, Kudchadkar, Ragini R., Linette, Gerald P., Gajewski, Thomas F., Lutzky, Jose, Lawson, David H., Lao, Christopher D., Flynn, Patrick J., Albertini, Mark R., Sato, Takami, Lewis, Karl, Doyle, Austin, Ancell, Kristin, Panageas, Katherine S., Bluth, Mark, Hedvat, Cyrus, Erinjeri, Joseph, Ambrosini, Grazia, Marr, Brian, Abramson, David, Dickson, Mark Andrew, Wolchok, Jedd D., Chapman, Paul B., Schwartz, Gary K.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249701/
https://ncbi.nlm.nih.gov/pubmed/24938562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2014.6096
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items